
    
      The objective of this phase 3 study is to assess the efficacy and safety of 0.05%
      difluprednate ophthalmic emulsion (DFBA) in patients with endogenous anterior uveitis, in
      comparison with 0.1% betamethasone sodium phosphate ophthalmic solution (BP).
    
  